BVF I GP LLC
CIK 1803805 · last filed 2025-01-14
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Loading insider history…
Disclosed Exposure
$246.55M
Companies
10
Total Filings
14
Lifetime Open-Market Net
$618.09M
Holdings By Company
Latest on-record share count from this person's most recent non-derivative Form 4 transaction in each company. Disclosed exposure = shares × current underlying price.
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| OLMA | Director | 2,103,522 | $10.43 | $21.94M | $0 | 1 | 2025-01-14 |
| FDMT | 87,911 | $11.47 | $1.01M | $0 | 1 | 2024-11-13 | |
| CGEM | 392,808 | $19.63 | $7.71M | $100.64M | 2 | 2023-01-19 | |
| RAIN | Director | 1,367,838 | $1.11 | $1.52M | $190.50M | 2 | 2022-11-10 |
| KYMR | Director | 1,466,364 | $109.62 | $160.74M | $151.66M | 2 | 2022-05-09 |
| INFINITY PHARMACEUTICALS, INC. (INFI) Delisted | 534,847 | $0.04 | $23.9K | -$121.33M | 1 | 2021-02-16 | |
| Merus N.V. (MRUS) Delisted | 10%+ Owner | 382,784 | $90.00 | $34.45M | $230.43M | 2 | 2020-12-22 |
| CRESCENT BIOPHARMA, INC. (GLYC) Delisted | 10%+ Owner | 37,124 | $15.70 | $582.8K | $32.94M | 1 | 2020-11-06 |
| FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | 10%+ Owner | 541,084 | $38.00 | $20.56M | $12.04M | 1 | 2020-05-18 |
| XOMA | 10%+ Owner | 1,335,192 | $40.17 | $53.63M | $21.22M | 1 | 2020-03-17 |
Recent Filings · Page 2 of 2
14 filingsInsider activity across all companies, newest first. Form 4 rows are post-trade confirmations (buys, sells, grants, exercises). Notice (144) rows are pre-trade notices of intent to sell restricted or control stock under Rule 144 — they may not all execute. Compare adjacent dates to see which notices became actual sales.
| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2020-11-06 | CRESCENT BIOPHARMA, INC. (GLYC) Delisted | Buy (P) | +12,667,370 | $32.94M | EDGAR |
| 2020-06-03 | Merus N.V. (MRUS) Delisted | Buy (P) | +14,625,100 | $204.75M | EDGAR |
| 2020-05-18 | FIVE PRIME THERAPEUTICS, INC. (FPRX) Delisted | Buy (P) | +2,935,870 | $12.04M | EDGAR |
| 2020-03-17 | XOMA | Buy (P) | +1,182,770 | $21.22M | EDGAR |
Showing 11–14 of 14
Prev
Page 2 of 2
Form 4 codes: P = open-market purchase · S = open-market sale · A = grant/award · M = option exercise · F = tax withholding at vest · G = bona-fide gift · D = disposition to issuer · J = other (see filing footnote). Only P / S codes carry directional signal.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.